講者：歐宴泉
日期：2016-05-10
觀看: 2938
  • 00:00 1.
    Novel Therapies for Patients with metastatic Prostate Cancer- Radium-223
  • 00:08 2.
    Application of Radiation in the Diagnosis and Treatment of Disease
  • 00:51 3.
    Radiation Used for Metastatic Prostate Cancer Patients
  • 01:11 4.
    External Beam Radiation Therapy (EBRT) for Patients With Metastatic Prostate Cancer
  • 01:24 5.
    β-Emitting, Bone-Targeted Radionuclide Treatments for mCRPC
  • 01:35 6.
    Radium Ra 223 Dichloride: First α-Emitting, Bone Metastasis–Targeted Therapeutic Radionuclide
  • 01:41 7.
    What Is Radium Ra 223 Dichloride?
  • 02:01 8.
    Radium Ra 223 Dichloride:Majority α-Decay, Minimal - and γ-Decay
  • 02:11 9.
    Radioactive Decay = Spontaneous Transformation of an Unstable Radionuclide Into Stable Elements
  • 02:22 10.
    Different Classes of Ionizing Radiation
  • 02:34 11.
    Penetration of Ionizing Radiation Types
  • 02:45 12.
    Radioactive Dose of Radium Ra 223 Dichloride Is Much Lower Compared With Commonly Used Radionuclides
  • 03:13 13.
    Radium Ra 223 Dichloride: Mechanism of Action
  • 03:14 14.
    Radium Ra 223 Dichloride Is Incorporated Into the Bone Mineral Hydroxyapatite1,2
  • 03:34 15.
    Radium Ra 223 Dichloride Has Preferential Uptake in Areas of New Bone Formation
  • 03:42 16.
    α-Particles Released by Radium Ra 223 Dichloride Cause Lethal Double-Strand DNA Breaks
  • 04:07 17.
    Short Range of α-Emitters Reduces Bone Marrow Exposure1
  • 04:17 18.
    β-Emitters: Long Radiation Range Increases Bone Marrow Exposure and Associated Toxicities1
  • 04:27 19.
    Radium Ra 223 Dichloride Dose Selection for Phase 3 Study
  • 05:11 20.
    Introduction to ALSYMPCA
  • 05:39 21.
    Slide 21
  • 05:55 22.
    ALSYMPCA: Study Design
  • 06:31 23.
    ALSYMPCA: Inclusion Criteria
  • 06:57 24.
    ALSYMPCA: Exclusion Criteria
  • 07:15 25.
    ALSYMPCA: Patient Demographics and Baseline Characteristics ITT Population
  • 07:41 26.
    ALSYMPCA: Patient Demographics and Baseline Characteristics ITT Population (cont’d)
  • 07:59 27.
    ALSYMPCA: ComplianceInjection Number
  • 08:16 28.
    ALSYMPCA: Updated AnalysisKaplan-Meier Estimates of Overall Survival
  • 08:55 29.
    ALSYMPCA: Updated Analysis Overall Survival Benefit Across Patient Subgroups
  • 09:26 30.
    Overall Survival was Significantly Improved with Radium-223, Regardless of Prior Docetaxel Use
  • 09:44 31.
    ALSYMPCA: Updated AnalysisMain Secondary Efficacy Endpoints
  • 10:43 32.
    ALSYMPCA Pain Analyses
  • 10:48 33.
    Time to Initial Opioid Use
  • 11:00 34.
    ALSYMPCA: Updated AnalysisKaplan-Meier Estimates of Time to First SSE
  • 11:15 35.
    Radium-223 Reduced the Risk of Each Individual SSE Component
  • 11:23 36.
    On-Study Use of EBRT as a Concomitant Procedure by Prior EBRT Usea (ITT Population, N=921)
  • 11:36 37.
    ALSYMPCA Efficacy: Biomarkers
  • 11:44 38.
    tALP Dynamics After Every Cycle of Treatment and at Two Follow-up Visits in the ITT Population
  • 12:12 39.
    ALSYMPCA: Updated AnalysisNumber of Patients With Adverse Events Occurringin ≥5% of Patients in Either Treatment Group
  • 12:20 40.
    ALSYMPCA: Updated AnalysisNumber of Patients With Adverse Events Occurringin ≥5% of Patients in Either Treatment Group (cont’d)
  • 12:23 41.
    ALSYMPCA Updated Analysis: Quality of Life FACT-Pa
  • 12:29 42.
    Radium-223 in Asia Patients with CRPC
  • 12:55 43.
    Conclusions Radium 223
  • 13:32 44.
    The future of Radium-223
  • 13:56 45.
    Xofigo 簡易仿單
  • 14:13 46.
    特殊警語與使用注意事項
  • 索引
  • 筆記
  • 全螢幕
【醫藥護人員場】4. Radium-223 (Xofigo, 鐳治骨)
長度: 14:47, 瀏覽: 2939, 最近修訂: 2017-05-09
演講時間：9:10-10:10
講者：歐宴泉主任
現任職位/稱：
臺中榮民總醫院泌尿外科主任
攝護腺疾病防治中心主任
中山醫學大學醫學博士
台灣泌尿科醫學會理事 
 
 
    上一篇 下一篇
    • 00:00 1.
      Novel Therapies for Patients with metastatic Prostate Cancer- Radium-223
    • 00:08 2.
      Application of Radiation in the Diagnosis and Treatment of Disease
    • 00:51 3.
      Radiation Used for Metastatic Prostate Cancer Patients
    • 01:11 4.
      External Beam Radiation Therapy (EBRT) for Patients With Metastatic Prostate Cancer
    • 01:24 5.
      β-Emitting, Bone-Targeted Radionuclide Treatments for mCRPC
    • 01:35 6.
      Radium Ra 223 Dichloride: First α-Emitting, Bone Metastasis–Targeted Therapeutic Radionuclide
    • 01:41 7.
      What Is Radium Ra 223 Dichloride?
    • 02:01 8.
      Radium Ra 223 Dichloride:Majority α-Decay, Minimal - and γ-Decay
    • 02:11 9.
      Radioactive Decay = Spontaneous Transformation of an Unstable Radionuclide Into Stable Elements
    • 02:22 10.
      Different Classes of Ionizing Radiation
    • 02:34 11.
      Penetration of Ionizing Radiation Types
    • 02:45 12.
      Radioactive Dose of Radium Ra 223 Dichloride Is Much Lower Compared With Commonly Used Radionuclides
    • 03:13 13.
      Radium Ra 223 Dichloride: Mechanism of Action
    • 03:14 14.
      Radium Ra 223 Dichloride Is Incorporated Into the Bone Mineral Hydroxyapatite1,2
    • 03:34 15.
      Radium Ra 223 Dichloride Has Preferential Uptake in Areas of New Bone Formation
    • 03:42 16.
      α-Particles Released by Radium Ra 223 Dichloride Cause Lethal Double-Strand DNA Breaks
    • 04:07 17.
      Short Range of α-Emitters Reduces Bone Marrow Exposure1
    • 04:17 18.
      β-Emitters: Long Radiation Range Increases Bone Marrow Exposure and Associated Toxicities1
    • 04:27 19.
      Radium Ra 223 Dichloride Dose Selection for Phase 3 Study
    • 05:11 20.
      Introduction to ALSYMPCA
    • 05:39 21.
      Slide 21
    • 05:55 22.
      ALSYMPCA: Study Design
    • 06:31 23.
      ALSYMPCA: Inclusion Criteria
    • 06:57 24.
      ALSYMPCA: Exclusion Criteria
    • 07:15 25.
      ALSYMPCA: Patient Demographics and Baseline Characteristics ITT Population
    • 07:41 26.
      ALSYMPCA: Patient Demographics and Baseline Characteristics ITT Population (cont’d)
    • 07:59 27.
      ALSYMPCA: ComplianceInjection Number
    • 08:16 28.
      ALSYMPCA: Updated AnalysisKaplan-Meier Estimates of Overall Survival
    • 08:55 29.
      ALSYMPCA: Updated Analysis Overall Survival Benefit Across Patient Subgroups
    • 09:26 30.
      Overall Survival was Significantly Improved with Radium-223, Regardless of Prior Docetaxel Use
    • 09:44 31.
      ALSYMPCA: Updated AnalysisMain Secondary Efficacy Endpoints
    • 10:43 32.
      ALSYMPCA Pain Analyses
    • 10:48 33.
      Time to Initial Opioid Use
    • 11:00 34.
      ALSYMPCA: Updated AnalysisKaplan-Meier Estimates of Time to First SSE
    • 11:15 35.
      Radium-223 Reduced the Risk of Each Individual SSE Component
    • 11:23 36.
      On-Study Use of EBRT as a Concomitant Procedure by Prior EBRT Usea (ITT Population, N=921)
    • 11:36 37.
      ALSYMPCA Efficacy: Biomarkers
    • 11:44 38.
      tALP Dynamics After Every Cycle of Treatment and at Two Follow-up Visits in the ITT Population
    • 12:12 39.
      ALSYMPCA: Updated AnalysisNumber of Patients With Adverse Events Occurringin ≥5% of Patients in Either Treatment Group
    • 12:20 40.
      ALSYMPCA: Updated AnalysisNumber of Patients With Adverse Events Occurringin ≥5% of Patients in Either Treatment Group (cont’d)
    • 12:23 41.
      ALSYMPCA Updated Analysis: Quality of Life FACT-Pa
    • 12:29 42.
      Radium-223 in Asia Patients with CRPC
    • 12:55 43.
      Conclusions Radium 223
    • 13:32 44.
      The future of Radium-223
    • 13:56 45.
      Xofigo 簡易仿單
    • 14:13 46.
      特殊警語與使用注意事項
    位置
    1. 知識庫
    2. ...
    3. 2016臺大攝護祭-醫藥護人員場
    資料夾名稱
    2016臺大攝護祭-醫藥護人員場
    發表人
    系統管理者
    單位
    泌尿部
    建立
    2016-05-10 12:25:00
    最近修訂
    2017-05-09 10:00:07
    長度
    14:47
    1. 知識庫
    2. ...
    3. 2016臺大攝護祭-醫藥護人員場
    1. 1.
      【醫藥護人員場】活動議程
    2. 2.
      【醫藥護人員場】1. Updates of Prostate Cancer Treatment Guidelines 2015/2016: EAU, NCCN, AUA
    3. 3.
      【醫藥護人員場】2. Prostate Cancer Screening、Observation、and Active Surveillance in Taiwan
    4. 4.
      【醫藥護人員場】3. Novel Therapies for Patients with Metastatic Prostate Cancer
    5. 5.
      【醫藥護人員場】4. Radium-223 (Xofigo, 鐳治骨)
    6. 6.
      【醫藥護人員場】5. Enzalutamide (Xtandi, 安可坦)
    7. 7.
      【醫藥護人員場】6. Denosumab (XGEVA, 癌骨瓦)
    8. 8.
      【醫藥護人員場】7. Long-term Treatment Outcomes for Localized Prostate Cancer by Risk Group Stratification in Taiwan-根除手術
    9. 9.
      【醫藥護人員場】8. Long-term Treatment Outcomes for Localized Prostate Cancer by Risk Group Stratification in Taiwan-放射治療
    10. 10.
      【醫藥護人員場】9. Long-term Treatment Outcomes for Localized Prostate Cancer by Risk Group Stratification in Taiwan-冷凍治療
    11. 11.
      【醫藥護人員場】10. Long-term Treatment Outcomes for Localized Prostate Cancer by Risk Group Stratification in Taiwan-HIFU治療
    12. 12.
      【醫藥護人員場】11. Long-term Treatment Outcomes for Localized Prostate Cancer by Risk Group Stratification in Taiwan-綜合比較與總結
    13. 13.
      【醫藥護人員場】12. Novel Life-Prolonging Endocrine Therapies for Metastatic Castration-Resistant Prostate Cancer
    14. 14.
      【醫藥護人員場】13. Medical and Surgical Treatment of Male Urinary Incontinence
    15. 15.
      【醫藥護人員場】14. Prevention and Management of Acute Urinary Retention in Men with Prostate Hypertrophy
    16. 16.
      【醫藥護人員場】15. The Art of Treatment for Nocturia
    17. 17.
      【醫藥護人員場】16. Storage Urinary Symptoms: 2016 Updates
    18. 18.
      【醫藥護人員場】17. Surgical Treatments for Prostate Hypertrophy with Urinary Symptoms 2016
    Copyright © 2017 TMUA, All rights reserved.